Enliven Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-14. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Enliven Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-14 | In | Kristine Ball | Director | 2026-10-14 | 8-K, 2026-10-14 |
Selling to them or working with them? See who runs Enliven Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Want the whole picture on Enliven Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Enliven Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enliven Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Leadership as last reported
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Kristine Ball, appointed, effective 2026-10-14 (filed 2026-10-14).
New leaders reset buying decisions — get the Full Report on Enliven Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Enliven Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Enliven Therapeutics, Inc.Every change, in the filing's words
Appointed: Kristine Ball, Director, effective 2026-10-14
On October 14, 2026, the board of directors (the "Board") of Enliven Therapeutics, Inc. (the "Company") increased the size of the Board from seven to eight directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders, and as a member of the Audit Committee of the Board (the "Audit Committee"), effective October 14, 2026.
Tools for this story
Each opens in a new tab, filled in for Enliven Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.